Coelomic Fluid of Eisenia fetida Ameliorates Cetuximab to Reduce K-Ras and Vimentin Expression through Promoting RUNX3 in an AOMDSS-Induced Colitis Associated Colon Cancer

Abstract EN

Ulcerative colitis is a major risk factor that increases the occurrence of colorectal cancer.

In colorectal cancer due to colitis, intestinal inflammation plays an important role which causes DNA damage.

The aim of this study is to investigate the anticancer effect of coelomic fluid of Eisenia fetida (CFEF) and cetuximab combinations.

Colitis associated colon cancer was induced in BALB/c mice by DSS/AOM.

The mice were randomly divided into six groups: group 1 received vehicle (control), groups 2–6 received DSS/AOM, groups 3–5 received cetuximab + CFEF (30, 60, or 120 mg/kgBW), and group 6 received CFEF only.

After the 12th week of treatments, the colon tissues were removed for histological examination and immune-fluorescence.

Intestinal Epithelial Cells (CECs) were analyzed by flow cytometer.

Administration of CFEF significantly decreased the severity of DSS/AOM-induced CAC in a dose-dependent manner.

The combinations of CFEF-cetuximab were revealed by histological change.

The CFEF significantly reduced the severity scores (P<0.05).

The combinations of CFEF-cetuximab significantly inhibited K-Ras and vimentin expressions, whereas the percentage of RUNX3 significantly increased in CECs.

The increasing of RUNX3 could prevent EMT, so that it can decrease K-Ras and vimentin to suppressed cell invasion and migration by CFEF.

Our results suggest that CFEF has the therapeutic potential to CAC.